European Journal of Nuclear Medicine and Molecular Imaging

Aims & Scope

The aim of the European Journal of Nuclear Medicine and Molecular Imaging is to provide a forum for the exchange of clinical and scientific information for the imaging community and allied professions involved in the functional, metabolic and molecular investigation of diseases.

The European Journal of Nuclear Medicine and Molecular Imaging will remain of primary interest to those practicing the field of imaging, radiopharmaceutical therapy and image guided therapy.

The field of interest includes advanced imaging analyses techniques and artificial intelligence application in the field of imaging.

Reports on original works related to physics, dosimetry, radiation biology, radiochemistry and pharmacy, will be considered in the field of interest of the EJNMMI.

The Journal will welcome original material reflecting the field of molecular imaging probes, reporter gene assays, cell trafficking, targeting of endogenous gene expression and antisense methodologies.

The Journal will continue to publish in depth Reviews of topical interest, Short communications, Controversies, interesting images and Letters to the editor.

Case reports are not published.

The journal publishes the following article types: Original article, Review article, Letter to the Editor, Guidelines, Controversies, Image of the month, Short Communications, Editorials

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	7.6
2024	8.60

Journal Rank

Year	Value
2024	1034

Journal Citation Indicator

Year	Value
2024	9118

SJR (SCImago Journal Rank)

Year	Value
2024	2.392

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	192

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

  Citation: 2572

  Authors: Ronald, Roberto, Wim J. G., Francesco, Klaus, Wolfgang, Fred J., Sally F., Lucy C., Wolfgang A., Sigrid, Dominique, Kevin J., Scott, Michael M., Giorgio, Otto S., Josee, Eric, Corneline J., Jan, Antoon, Bertjan, Jörg, Andreas, Thomas, Arturo, Bernd J.

• FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0

  Citation: 1052

  Authors: Ronald, Mike J., Wolfgang A., Felix M., Markus N., Sigrid G., Wim J. G., Joerg, Otto S., Jan, Paul K., Klaus, Corneline J., Eric P., Bertjan, Fred J., Josee M., Emile F. I., Adriaan A., Anne M., Antoon T., Thomas, Andreas, Cornelia, Dominique, Richard P., Arturo, Bernd J.

• Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

  Citation: 866

  Authors: Jean Claude, Jean-Claude, Beatrice, Sandra, Axel, Jörg S., Helmut R.

• The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

  Citation: 835

  Authors: Ali, Eleni, Frederik L., Tim, Heinz G., Matthias, Michael, Silvan, Boris A., Clemens, Wilko, Klaus, Jürgen, Uwe

• Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

  Citation: 772

  Authors: Ali, Christian M., Anna, Matthias, Michael, Heinz G., Tim, Boris A., Frederik L., Jürgen, Uwe

• PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

  Citation: 765

  Authors: A., A., M., M., H. G., B. A., T., F. L., C., S., U., C. M.

• Brain glucose metabolism in the early and specific diagnosis of Alzheimer?s disease

  Citation: 708

  Authors: Lisa

• 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0

  Citation: 629

  Authors: Wolfgang P., Matthias, Mohsen, Jamshed, Francesco, Steven, Frederik, Uwe, Thomas A., Klaus, Bernd J., Felix M., Heiko, John, Simon, Hans-Jürgen, Stefano, Ken

• The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

  Citation: 628

  Authors: John J., L., J., M. E., R. P., D., M. S., T. M., J. R., M., D. J.

• Guidelines for radioiodine therapy of differentiated thyroid cancer

  Citation: 546

  Authors: M., S. E., M., M., P., W. J. G., J., E.

---